Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 701–800 of 1,002
Neef, V., Schmitt, E., Bader, P., Zierfuß, F., Hintereder, G., Steinbicker, A. U., Zacharowski, K. D., & Piekarski, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163506 · Cited by 27
“[26] and the diagnosis and treatment of iron deficiency guidelines [27–29].”
BackgroundFitzsimons, S., Poppe, K., Choi, Y. C., Devlin, G., Lund, M., Lam, C. S. P., Troughton, R. W., Richards, M., & Doughty, R. N. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.018 · Cited by 23
Treatment of Iron Deficiency in Heart Failure
Shamsi, A., Cannata, A. N., Piper, S. E., Bromage, D. I., & McDonagh, T. A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01889-4 · Cited by 26
Silverberg, D. S., Schwartz, D., Schwartz, I. F., & Ben–Assa, E. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.249 · Cited by 22
Anemia in Heart Failure: an Overview of Current Concepts
von Haehling, S., Jankowska, E. A., Ponikowski, P. P., & Anker, S. D. (2010) · Future Cardiology · doi:10.2217/fca.10.110 · Cited by 24
Self-citationAnemia in heart failure. Should we supplement iron in patients with chronic heart failure?
Kaldara‐Papatheodorou, E. E., Terrovitis, J. V., & Nanas, J. N. (2010) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.967 · Cited by 26
Mikkelsen, L. F., Nordestgaard, B. G., Schnohr, P., & Ellervik, C. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.292763 · Cited by 24
Anemia and iron deficiency in heart failure: a review of echocardiographic features
Sutil‐Vega, M., Rizzo, M., & Martínez‐Rubio, A. (2019) · Echocardiography · doi:10.1111/echo.14271 · Cited by 28
Iron Deficiency in Acute Decompensated Heart Failure
Beale, A. L., Carballo, D., Stirnemann, J., Garin, N., Agoritsas, T., Serratrice, J., Kaye, D. M., Meyer, P., & Carballo, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101569 · Cited by 23
“Intravenous iron therapy with ferric carboxymaltose is established as an important treatment for patients with HFrEF, improving functional capacity, symptoms of heart failure, quality of life, and reducing heart failure hospitalizations [34,35].”
BackgroundNew diagnostic tools for delineating iron status
Ginzburg, Y. Z. (2019) · Hematology · doi:10.1182/hematology.2019000035 · Cited by 23
Bouabdallaoui, N., O'Meara, E., Bernier, V., Komajda, M., Swedberg, K., Tavazzi, L., Borer, J. S., Bohm, M., Ford, I., & Tardif, J.-C. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12513 · Cited by 21
“and non-pharmacological interventions have recently been demonstrated to be associated with better outcomes, especially when co-occurring with improvements in cardiac status.(17,18) However, the specific impacts of guidelinedirected medical therapy (GDMT), and particularly ivabradine, on PRO (i.”
BackgroundVolterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad400 · Cited by 22
Self-citationLitton, E., Baker, S., Erber, W. N., French, C., Ferrier, J., Hawkins, D., Higgins, A. M., Hofmann, A., Keulenaer, B. L. D., Farmer, S. L., et al. (2014) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01621-6 · Cited by 25
Rognoni, C., & Gerzeli, S. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0074 · Cited by 23
Chung, B., Wang, Y., Thiel, M., Rostami, F., Rogoll, A., Hirsch, V. G., Malik, Z., Bührke, A., Bär, C., Klintschar, M., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad092 · Cited by 25
Greenwood, S. A., Oliveira, B. A., Asgari, E., Ayis, S. A., Baker, L. A., Beckley‐Hoelscher, N., Goubar, A., Banerjee, D., Bhandari, S., Chilcot, J., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.05.002 · Cited by 21
Park, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0016 · Cited by 22
Martens, P., Augusto, S. N., Müllens, W., & Tang, W. H. W. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.11.006 · Cited by 23
Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis
Ioannou, A., Nitsche, C., Porcari, A., Patel, R., Razvi, Y., Rauf, M., Martinez-Naharro, A., Venneri, L., Accietto, A., Netti, L., et al. (2024) · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · doi:10.1161/jaha.123.033094 · Cited by 17
“19,20 Currently, tafamidis (a highly specific transthyretin stabilizer) is the only treatment proven to improve prognosis in ATTR-CA, but despite efficacy, the associated high cost has resulted in restricted use.”
BackgroundVecchio, L. D., Girelli, D., Vinchi, F., Cozzolino, M. G., Elliott, S., Mark, P. B., Valenti, L. V. C., Qian, C., Guo, Q., Qian, Z., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae095 · Cited by 31
Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients
Schou, M., Bosselmann, H. S., Gaborit, F., Iversen, K. K., Goetze, J. P., Soletomas, G., Rasmussen, J., Kistorp, C., Køber, L., Gustafsson, F., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.096 · Cited by 21
Yoon, H. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1852 · Cited by 21
Role of Iron Deficiency and Anemia in Cardio-Renal Syndromes
Attanasio, P., Ronco, C., Anker, S. D., Cicoira, M., & von Haehling, S. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.11.008 · Cited by 23
Self-citationThe prognostic significance of early and late anaemia in acute coronary syndrome
Ang, D. S. C., Kao, M. P. C., Noman, A., Lang, C. C., & Struthers, A. D. (2011) · QJM · doi:10.1093/qjmed/hcr258 · Cited by 21
Silencing of hepcidin enforces the apoptosis in iron-induced human cardiomyocytes
Hsieh, Y., Huang, C.-H., Lee, C.-Y., Lin, C., & Chang, C. (2014) · Journal of Occupational Medicine and Toxicology · doi:10.1186/1745-6673-9-11 · Cited by 23
Anämie und Eisenmangel in der Geriatrie: Prävalenz, Diagnostik und neue Therapieoptionen
Röhrig, G., Doehner, W., Schaefer, R. M., & Schulz, R. J. (2012) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-012-0320-8 · Cited by 24
Cardiac Hepcidin Expression Associates with Injury Independent of Iron
van Breda, G. F., Bongartz, L. G., Zhuang, W., van Swelm, R. P. L., Pertijs, J. C. L. M., Braam, B. G., Cramer, M. J., Swinkels, D. W., Doevendans, P. A., Verhaar, M. C., et al. (2016) · American Journal of Nephrology · doi:10.1159/000449419 · Cited by 21
Meroño, O., Cladellas, M., Ribas, N., Poveda, P. M., Recasens, L., Bazán, V., García‐García, C., Ivern, C., Enjuanes, C., Orient, S., et al. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.10.004 · Cited by 21
Kobak, K. A., Kasztura, M., Dzięgała, M., Bania, J., Kapusniak, V., Banasiak, W., Ponikowski, P. P., & Jankowska, E. A. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3481 · Cited by 23
“The beneficial effects of iron supplementation on the improvement of muscle function in patients with HF have already been reported (22,23); however, the associated mechanisms remain to be elucidated.”
BackgroundSelf-citationPrevalence of Underlying Gastrointestinal Malignancies in Iron-Deficient Heart Failure
Martens, P., Minten, L., Dupont, M., & Müllens, W. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12379 · Cited by 22
Bourguignon, S., Faller, M., Champs, F., Moutier, H., Lévesque, K., Caranhac, G., & Solal, A. C. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12432 · Cited by 21
Iron deficiency as therapeutic target in heart failure: a translational approach
Bakogiannis, C., Briasoulis, Α., Mouselimis, D., Tsarouchas, A., Παπαγεωργίου, Ν., Papadopoulos, C. E., Fragakis, N., & Vassilikos, V. P. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09815-z · Cited by 24
A Modern Integration of Palliative Care Into the Management of Heart Failure
Puckett, C., & Goodlin, S. J. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.05.004 · Cited by 21
Iron deficiency and supplementation in heart failure and chronic kidney disease
Punj, S., Ghafourian, K., & Ardehali, H. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100873 · Cited by 23
Englund, K., Østby, C. M., Rolid, K., Gude, E., Andreassen, A. K., Gullestad, L. L., & Broch, K. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.01.1390 · Cited by 23
Pathophysiology of Advanced Heart Failure
Biegus, J., Niewiński, P., Josiak, K., Kulej, K., Ponikowska, B., Nowak, K., Zymliński, R., & Ponikowski, P. P. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.06.001 · Cited by 25
Self-citationMakharadze, T., Boccia, R. V., Krupa, A., Blackman, N. J., Henry, D. H., & Gilreath, J. A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26376 · Cited by 21
Cardiorenal Syndromes in Critical Care
Ronco, C., Bellomo, R., & McCullough, P. A. (2010) · Contributions to nephrology · doi:10.1159/isbn.978-3-8055-9473-8 · Cited by 22
Correction of Iron Deficiency in the Cardiorenal Syndrome
Silverberg, D. S., Wexler, D., Iaina, A., & Schwartz, D. (2011) · International Journal of Nephrology · doi:10.4061/2011/365301 · Cited by 21
Management of Iron Deficiency in Heart Failure
Kido, K., Beavers, C. J., Dulnuan, K., Fida, N., Guglin, M. E., Ilonze, O. J., Mentz, R. J., Narang, N., Rajagopalan, N., Ramu, B., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.014 · Cited by 24
Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF)
Pecchia, B., Samuel, R., Shah, V., Newman, E., & Gibson, G. T. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10504-3 · Cited by 26
“…found that intravenous iron therapy significantly improved endurance capacity and symptoms, evidenced by improvement in peak VO 2 , increased in distance on 6-min walk test, and improvement in New York Heart Associated (NYHA) functional class, as well as improved quality of life (QOL) [113, 114].”
Prevalence of anemia among elderly patients in an emergency room setting
Röhrig, G., Klossok, W., Becker, I., Benzing, T. R., & Schulz, R. J. (2013) · European Geriatric Medicine · doi:10.1016/j.eurger.2013.10.008 · Cited by 24
Terrovitis, J. V., Kaldara, E. E., Ntalianis, A., Sventzouri, S., Kapelios, C. J., Barbarousi, D., Matsouka, C., & Nanas, J. N. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.05.065 · Cited by 20
Waldvogel-Abramovski, S., Waeber, G., Gassner, C., Buser, A. S., Frey, B. M., Favrat, B., & Tissot, J. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.10.001 · Cited by 21
The emerging role of iron in heart failure and vascular calcification in CKD
Ciceri, P., & Cozzolino, M. G. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa135 · Cited by 21
“Ferinject Assessment in Patients with Iron Deficiency and Chronic HF is a large randomized study [11].”
BackgroundCanning, M. L., & Grannell, L. (2020) · Australian Prescriber · doi:10.18773/austprescr.2020.051 · Cited by 22
Herzinsuffizienzleitlinien 2021 der ESC
Bauersachs, J. K., & Soltani, S. (2021) · Herz · doi:10.1007/s00059-021-05084-5 · Cited by 23
“Dies war nach der FAIR-HF- [3] und der CONFIRM-HF-Studie [25] bereits in den letzten Leitlinien empfohlen worden.”
BackgroundMartens, P., Dupont, M., Dauw, J., Nijst, P., Bertrand, P. B., Tang, W. H. W., & Müllens, W. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2489 · Cited by 21
The impact of intravenous iron supplementation in elderly patients undergoing major surgery
Blum, L. V., Zierentz, P., Hof, L., Kloka, J. A., Messroghli, L., Zacharowski, K. D., Meybohm, P., & Choorapoikayil, S. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-02983-y · Cited by 22
Packer, M., & Cleland, J. G. F. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.12.007 · Cited by 20
Graham, F. J., Pellicori, P., Masini, G., Cuthbert, J. J., Clark, A. L., & Cleland, J. G. F. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14438 · Cited by 26
Pharmacologic Management of the Cardio-renal Syndrome
Kim, C. S. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.1.17 · Cited by 20
Hasenfuss, G. P., Anker, S. D., Bauersachs, J. K., Böhm, M., Hoppe, U. C., Pieske, B. M., von Scheidt, W., & Wachter, R. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0491-6 · Cited by 28
Self-citationPozzo, J., Fournier, P., Delmas, C., Vervueren, P., Roncalli, J. G., Elbaz, M., Galinier, M., & Lairez, O. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2016.06.003 · Cited by 22
Amione‐Guerra, J., Cruz-Solbes, A. S., Bhimaraj, A., Trachtenberg, B. H., Pingali, S. R., Estep, J. D., Park, M., & Guha, A. (2017) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000607 · Cited by 21
Current Therapeutic Options for Heart Failure in Elderly Patients
Guerra, F., Brambatti, M., Matassini, M. V., & Capucci, A. (2017) · BioMed Research International · doi:10.1155/2017/1483873 · Cited by 22
Intravenous iron: out of sight, out of mind
Auerbach, M., Múñoz, M., & Macdougall, I. C. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30230-2 · Cited by 20
Fadini, G. P., Sarangdhar, M., & Avogaro, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0408-2 · Cited by 23
“Iron was excluded as anemia, which is a risk factor for HF, can be improved by iron supplementation [23].”
BackgroundRuhe, J., Waldeyer, C., Ojeda, F., Altay, A., Schnabel, R. B., Schäfer, S., Lackner, K. J., Blankenberg, S., Zeller, T., & Karakas, M. (2018) · Biomolecules · doi:10.3390/biom8030072 · Cited by 20
“Moreover, within the FAIR-HF, in which two thirds of patients had CAD as underlying etiology of heart failure, the beneficial effects of intravenous iron supplementation were completely independent of hemoglobin levels as treatment with ferric carboxymaltose was beneficial to patients with and without anemia [20].”
BackgroundKvaslerud, A. B., Hussain, A. I., Auensen, A., Ueland, T., Michelsen, A. E., Pettersen, K. I., Aukrust, P., Mørkrid, L., Gullestad, L. L., & Broch, K. (2018) · Open Heart · doi:10.1136/openhrt-2018-000901 · Cited by 25
“Total iron binding capacity (TIBC) 64 (11) 67 (11) 50 (9) <0.”
Reddy, Y. N. V., Borlaug, B. A., O’Connor, C. M., & Gersh, B. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz364 · Cited by 24
PCB-77 disturbs iron homeostasis through regulating hepcidin gene expression
Wang, L., Zhang, S., Lin, R., Li, L., Zhang, D., Li, X., & Liu, S. (2013) · Gene · doi:10.1016/j.gene.2013.09.023 · Cited by 19
Heart Failure in Older Patients: An Update
Montalto, M., D'Ignazio, F., Camilli, S., Francesco, S. D., Fedele, M., Landi, F., & Gallo, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061982 · Cited by 26
“…particularly with ferric carboxymaltose, improves symptoms (with an increase in NYHA class and exercise capacity) and quality of life [154] and reduces hospitalization rates [155–157], without, however, providing benefits related to reducing cardiovascular and all-cause mortality…”
Ueda, T., Kawakami, R., Nogi, K., Nogi, M., Ishihara, S., Nakada, Y., Nakano, T., Hashimoto, Y., Nakagawa, H., Nishida, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82063-0 · Cited by 22
Cardiac Surgery and Blood-Saving Techniques: An Update
Yousuf, M. S., Samad, K., Ahmed, S. S., Siddiqui, K. M., & Ullah, H. (2022) · Cureus · doi:10.7759/cureus.21222 · Cited by 35
“Intravenous iron has been shown to be effective and safe [12].”
BackgroundApplicability of New Proposed Criteria for Iron Deficiency in Japanese Patients with Heart Failure
Tada, A., Nagai, T., Koya, T., Nakao, M., Ishizaka, S., Mizuguchi, Y., Aoyagi, H., Imagawa, S., Tokuda, Y., Takahashi, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14265 · Cited by 19
Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease?
Buliga-Finiș, O. N., Ouatu, A., Tănase, D. M., Gosav, E. M., Isac, P. N. S., Richter, P., & Rezuș, C. (2023) · Life · doi:10.3390/life13061311 · Cited by 23
“73 m2 and chronic heart failure who received intravenous ferric carboxymaltose in the Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) trial [7].”
BackgroundPeri, V., Devlin, P., Perry, L. A., Richards, T., & Miles, L. F. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006822 · Cited by 23
Ohno, Y., Hanawa, H., Jiao, S., Hayashi, Y., Yoshida, K., Suzuki, T., Kashimura, T., Obata, H., Tanaka, K., Watanabe, T., et al. (2015) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.235.69 · Cited by 20
Medication Management of Chronic Heart Failure in Older Adults
Alagiakrishnan, K., Banach, M., Jones, L. G., Ahmed, A., & Aronow, W. S. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0105-9 · Cited by 22
Tarantini, L., Oliva, F. G., Cantoni, S., Cioffi, G., Agnoletto, V., Alunni, G., Cian, F. D., Lenarda, A. D., Lucci, D., Pulignano, G., et al. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0601-z · Cited by 23
OWENS, A. T., & Jessup, M. L. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.064 · Cited by 20
Múñoz, M., Gómez‐Ramírez, S., Martín‐Montañez, E., Pavía, J., Cuenca, J., & García‐Erce, J. A. (2012) · PubMed · doi:10.3305/nh.2012.27.6.6087 · Cited by 22
Senthong, V., Hudec, T., Neale, S., Wu, Y., Hazen, S. L., & Tang, W. H. W. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.01.036 · Cited by 21
Nakagawa, Y., Ohta, S., Sugahara, A., Okubo, M., Yamada, A., & Ito, T. (2017) · Macromolecules · doi:10.1021/acs.macromol.7b01020 · Cited by 19
Besarab, A., & Hemmerich, S. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7360-6_2 · Cited by 27
Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials
Bhatt, K., & Butler, J. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0386-8 · Cited by 22
Salisbury, A. C., Amin, A. P., Reid, K. J., Wang, T. Y., Alexander, K. P., Chan, P. S., Masoudi, F. A., Spertus, J. A., & Kosiborod, M. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.11.045 · Cited by 19
Motonishi, S., Tanaka, K., & Ozawa, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201662 · Cited by 23
First trimester ferritin screening for pre-delivery anaemia as a patient blood management strategy
Crispin, P. J., Stephens, B., McArthur, E., & Sethna, F. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.11.009 · Cited by 25
Ambrosy, A. P., Lewis, G. D., Malhotra, R. K., Jones, A. D., Greene, S. J., Fudim, M., Coles, A., Butler, J., Sharma, A., Hernandez, A. F., et al. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000736 · Cited by 21
Mistry, R. H., Kohut, A. R., & Ford, P. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04338-2 · Cited by 32
Co-Morbidities in Heart Failure Beginning to Sprout—and no end in Sight?
von Haehling, S. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1098 · Cited by 19
Parcha, V., Patel, N., Kalra, R., Bhargava, A., Prabhu, S. D., Arora, G., & Arora, P. K. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.006 · Cited by 19
HFE Genotype and Endurance Performance in Competitive Male Athletes
Thakkar, D., Sicova, M., Guest, N. S., García‐Bailo, B., & El‐Sohemy, A. (2020) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002595 · Cited by 22
Anemia and Management of Heart Failure Patients
Beladan, C. C., & Botezatu, S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.12.002 · Cited by 25
Bhandari, S. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4958 · Cited by 19
Gevaert, A. B., Mueller, S., Winzer, E. B., Duvinage, A., Heyning, C. M. V. D., Pieske‐Kraigher, E., Beckers, P. J., Edelmann, F., Wisløff, U., Pieske, B. M., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.757268 · Cited by 21
Herfs, R., Fleitmann, L., & Kocsis, I. (2014) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0033-1360223 · Cited by 18
Toblli, J. E., & Gennaro, F. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125528 · Cited by 20
Kaminsky, B. M., Pogue, K. T., Hanigan, S., Koelling, T. M., & Dorsch, M. P. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.041 · Cited by 18
Manito, N., Cerqueiro, J. M., Colet, J. C., García‐Pinilla, J. M., Franco, Á. G., Amorós, J. G., Peraira, J. R., & Manzano, L. (2016) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2016.10.003 · Cited by 21
Safety of intravenous iron in hemodialysis patients
Li, X., Kshirsagar, A. V., & Brookhart, M. A. (2017) · Hemodialysis International · doi:10.1111/hdi.12558 · Cited by 21
Hannedouche, T. P., Fouque, D. P., & Joly, D. A. (2018) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(18)30647-3 · Cited by 24
The link between anemia and adverse outcomes in patients with acute coronary syndrome
Guedeney, P., Sorrentino, S., Claessen, B. E. P. M., & Mehran, R. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1575729 · Cited by 24
González‐Costello, J., Cainzos‐Achirica, M., Lupón, J., Farré, N., Moliner, P., Enjuanes, C., de Antonio, M., Fuentes, L., Díez‐López, C., Bayés‐Genís, A., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.031 · Cited by 22
Zhang, J., Hu, S., Jiang, Y., & Zhou, Y. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137342 · Cited by 19
Personalizing heart failure management in chronic kidney disease patients
Banerjee, D., & Wang, A. Y.-M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab026 · Cited by 22
Merkaš, I. S., Slišković, A. M., & Lakušić, N. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i7.183 · Cited by 23
Yamani, N., Ahmed, A. B., Gosain, P., Fatima, K., Shaikh, A. T., Qamar, H., Shahid, I., Arshad, M. S., Almas, T., & Figueredo, V. M. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100871 · Cited by 19
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.